外泌体包膜AAV载体增强肝脏基因转移并规避预存体液免疫
该研究评估外泌体相关AAV(exo-AAV)载体作为肝脏基因递送系统的效果与规避预存体液免疫的能力。在血友病B小鼠中,4×10^10 vg/kg的exo-AAV8使hF.IX表达较标准AAV8提高约1个对数级,并改善凝血时间纠正;exo-AAV8在中等中和抗体滴度下仍能有效转导,可能扩大适合肝脏基因转移的受试者比例。
要点
- exo-AAV8在血友病B小鼠中使hF.IX表达较标准AAV8提高约1个对数级。
- exo-AAV8在中等NAb滴度下仍能有效转导,可能扩大适用人群。
- exo-AAV载体是提高肝脏基因转移安全性与疗效的平台。
核心结论
- 外泌体相关AAV载体是提高肝脏定向基因转移安全性和疗效的平台。
研究设计与样本
- 在血友病B小鼠中比较标准AAV8或AAV5与exo-AAV8或exo-AAV5表达人凝血因子IX的肝脏靶向体内效率。
- 在被动免疫小鼠模型和人血清中评估exo-AAV8与标准AAV8规避预存中和抗体的效率。
主要发现
- 观察到转导效率显著增强,血友病B小鼠接受4×10^10 vg/kg exo-AAV8后hF.IX转基因表达较标准AAV8提高约1个对数级,凝血时间纠正更优。
- 肝脏表达增强伴随淋巴结调节性T细胞频率增加。
- exo-AAV8基因递送在中等NAb滴度存在时仍能有效转导。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Results from clinical trials of liver gene transfer for hemophilia demonstrate the potential of the adeno-associated virus (AAV) vector platform. However, to achieve therapeutic transgene expression, in some cases high vector doses are required, which are associated with a higher risk of triggering anti-capsid cytotoxic T-cell responses. Additionally, anti-AAV preexisting immunity can prevent liver transduction even at low neutralizing antibody (NAb) titers. Here, we describe the use of exosome-associated AAV (exo-AAV) vectors as a robust liver gene delivery system that allows the therapeutic vector dose to be decreased while protecting from preexisting humoral immunity to the capsid. The in vivo efficiency of liver targeting of standard AAV8 or AAV5 and exo-AAV8 or exo-AAV5 vectors expressing human coagulation factor IX (hF.IX) was evaluated. A significant enhancement of transduction efficiency was observed, and in hemophilia B mice treated with 4 × 1010 vector genomes per kilogram of exo-AAV8 vectors, a staggering ∼1 log increase in hF.IX transgene expression was observed, leading to superior correction of clotting time. Enhanced liver expression was also associated with an increase in the frequency of regulatory T cells in lymph nodes. The efficiency of exo- and standard AAV8 vectors in evading preexisting NAbs to the capsid was then evaluated in a passive immunization mouse model and in human sera. Exo-AAV8 gene delivery allowed for efficient transduction even in the presence of moderate NAb titers, thus potentially extending the proportion of subjects eligible for liver gene transfer. Exo-AAV vectors therefore represent a platform to improve the safety and efficacy of liver-directed gene transfer.
引用
- Meliani A, Boisgerault F, Fitzpatrick Z, et al. Enhanced liver gene transfer and evasion of preexisting humoral immunity with exosome-enveloped AAV vectors. Blood Adv. 2017. PMID: 29296848. doi:10.1182/bloodadvances.2017010181
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。